Mandate

Vinge advises Axcel and Sanviva on the acquisitions of DermaCura and YourRad

Vinge has advised Axcel Elevate I and Sanviva in connection with the acquisitions of DermaCura and YourRad.

DermaCura is a Dutch family-owned company specialising in medical devices for patients with chronic skin conditions. Through the acquisition of DermaCura, Sanviva strengthens its position in the Benelux region and expands its product portfolio with adjacent products in dermatology. YourRad is an entrepreneur-led company engaged in the distribution of radiotherapy equipment, consumables and related medical devices in the Nordics. Through the acquisition of YourRad, Sanviva strengthens its position in the Nordics and expands its product portfolio to include specialised products in radiotherapy and oncology.

Sanviva is a distribution network for medical devices that combines local sales, distribution and market expertise to provide suppliers with access to healthcare markets in Europe. Sanviva operates in the Nordics and Benelux with a product portfolio that includes, among other things, wound care, stoma care, in vitro diagnostics and adjacent products.

The Vinge team consisted of Christina Kokko, Egil Svensson, Ida Appelgren, Lina Björkman and Celina Kristiansson (M&A), Christoffer Nordin and Katja Häglund (Corporate Commercial),  Nilufer Nouri (Banking and Finance), Louisa Fagarasan och Linn Aho (Employment Law), Dagne Sabockis (FDI) and Filippa Bergkvist (Transaction Support Coordinator).

Read the client's press releases here and here.

Related

Vinge has advised Oncopeptides in connection with a directed share issue

Vinge has advised Oncopeptides in connection with a directed share issue, whereby Oncopeptides raises proceeds of SEK 100 million.
October 16, 2026

Vinge advises KGAL on its divestment of a Nordic wind portfolio to Enordic Evergreen

Vinge has advised KGAL on the divestment of a Nordic onshore wind portfolio to Enordic Evergreen.
October 14, 2026

Vinge has advised Orexo in connection with its rights issue

Vinge has advised Orexo AB (publ) in connection with a partially guaranteed rights issue of approximately SEK 250 million before transaction costs, subject to approval by an extraordinary general meeting.
October 09, 2026